My dear colleagues, this month’s issue of Parkinsonism and Related Disorders features a Point of View paper by Espay et al entitled, “The α-Synuclein Seed Amplification Assay: Interpreting a Test of Parkinson’s Pathology” [1]. In this article, the authors caution those who jump on the synuclein bandwagon all too quickly. They present their viewpoints regarding the weaknesses of using alpha synuclein seed amplification assay (αSyn-SAA) as a basis for the biological staging of Parkinson disease (PD).